Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.
Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.
Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
If Fierce Pharma Marketing’s annual list of the top 10 biggest potential drug launches of the coming year is any indication, ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Zacks Investment Research on MSN4d
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe UpdateAstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus ...
The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...
Zacks Investment Research on MSN6d
Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 ViewMerck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...
Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...
The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback